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PUK11
COST-MINIMIZATION ANALYSIS: MIRCERA (METHOXY 
POLYETHYLENE GLYCOL-EPOETIN BETA) VS. ARANESP 
(DARBEPOETIN ALFA) IN PATIENTS WITH CHRONIC KIDNEY  
DISEASE (CKD) WHO ARE NOT RECEIVING HAEMODIALYSIS,  
IN POLISH SETTING
Kawalec P1, Kuzma J1, Szkultecka-Debek M2, Russel-Szymczyk M2, Slizien-Debska A3, 
Malyszko J4, Durlik M5
1Centrum HTA, Krakow, Poland, 2Roche Polska, Warsaw, Poland, 3Medical University of 
Gdansk, Gdansk, Poland, 4Medical University of Bialystok, Bialystok, Poland, 5Warsaw Medical 
University, Warsaw, Poland
OBJECTIVES: To assess and compare costs and effects of Mircera vs. Aranesp treat-
ment of pre-dialysis patients. METHODS: A systematic review of medical data bases 
according to EBM principles was conducted. Efﬁcacy and safety data for both treat-
ment options were compared. No signiﬁcant differences in clinical efﬁcacy and safety 
of both treatments were identiﬁed. Cost-minimization analysis was conducted in order 
to compare costs. The analysis was performed from the perspective of public payer in 
a two-year time horizon. Only direct cost data, gathered in three reference centers in 
Poland, were taken into account (drug’s costs, drug administration and adverse events 
costs). According to Polish HTA Agency guidelines costs were discounted by 5%. 
Dosing schemes for both drugs were assumed based on the assumptions of the 
National Health Fund Therapeutic Area Program for the CKD patients in pre-dialysis 
period: Mircera- 50 Mg s.c.(mean monthly dose), Aranesp: 10 Mg once weekly, or 
20 Mg—once per 2 weeks or 40 Mg once monthly i.v. or s.c (mean dosing was calcu-
lated). Sensitivity analysis was done to test the robustness of the results. Results were 
tested for changes in the value of accounting points deﬁned by the payer (/20%), 
discounting rate for costs and changes in drug dosing. RESULTS: CMA showed 
savings of 1 194 PLN (1 EUR  4.55 PLN) per patient with Mircera treatment vs. 
Aranesp in the 2 year horizon. Savings were due to the once monthly Mircera admin-
istration scheme. Results of the basic analysis were conﬁrmed by the sensitivity analy-
sis. CONCLUSIONS: Mircera treatment of CKD patients in pre-dialysis period is as 
effective and safe as Aranesp therapy, but offers savings to the public payer.
PUK12
COST-EFFECTIVENESS OF ACE INHIBITOR THERAPY TO PREVENT 
DIALYSIS IN NON-DIABETIC NEPHROPATHY—INFLUENCE OF THE 
ACE INSERTION / DELETION POLYMORPHISM
Vegter S1, Perna A2, Hiddema W1, Ruggenenti P2, Remuzzi G2, Navis G3, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Mario Negri Institute for 
Pharmacological Research, Ranica, Italy, 3University Medical Centre Groningen (UMCG), 
Groningen, The Netherlands
OBJECTIVES: End Stage Renal Disease (ESRD) is associated with high health care           
costs and low quality of life (QoL) compared to Chronic Kidney Disease (CKD). The 
renoprotective effectiveness of ACE inhibitors (ACEi) is largely determined by the ACE 
insertion deletion (I/D) polymorphism. We determined the cost-effectiveness of ACEi 
therapy in non-diabetic nephropathy for the ACE II/ID and for the ACE DD genotype. 
Furthermore, we considered a selective screen-and-treat strategy where patients are 
prescriped alternative therapy based on their ACE (I/D) polymorphism. METHODS: 
Time-dependent Markov models were constructed; cohorts of 1000 patients were 
followed for 10 years. Data were mainly gathered from the Ramipril Efﬁcacy In 
Nephropathy (REIN) trial. Both univariate and probabilistic sensitivity analyses were 
performed. RESULTS: ACEi therapy compared to placebo both reduces costs and         
improves QALY’s more in the ACE DD group (a105,104 and 0.553 QALYs gained 
per patient) than in the ACE II/ID group (a15,826 and 0.091 QALYs gained). 
Sensitivity analyses demonstrated a 30.2% probability of ACEi therapy being not 
cost-effective in the ACE II/ID group, against an almost 100% probability of cost-
effectiveness in the ACE DD group. Cost of dialysis had the largest inﬂuence on the 
cost-effectiveness. An alternative treatment for patients with the ACE II/ID genotype, 
incorporated in a selective screen-and-treat strategy, should feature a 9.1% increase 
in survival time for the strategy to be cost-effective. High alternative treatment 
effectiveness and dialysis costs improve the cost-effectiveness of a screening strategy. 
CONCLUSIONS: ACEi therapy is a cost saving treatment in non diabetic nephropathy,           
irrespectively of ACE (I/D) genotype. However, ACEi therapy saved more costs and 
more health gaines were achieved in the ACE DD genotype than in the ACE II/ID 
genotype. An alternative treatment featuring a modest increase in survival time for 
patients with the ACE II/ID genotype can be incorporated in a cost-effective screen-
and-treat strategy.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
PUK13
DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE (SIGIT-QOL) 
TO EVALUATE THE EFFECTS OF GASTROINTESTINAL SYMPTOMS ON 
HEALTH RELATED-QUALITY OF LIFE IN SOLID-ORGAN TRANSPLANT 
RECIPIENTS WITH A FUNCTIONING GRAFT
Font B1, Mora S1, Lahoz R1, Ortega F2, Mypaciente Study Group1
1Novartis Farmaceutica SA, Barcelona, Spain, 2Hospital Universitario Central de Asturias, 
Oviedo, Spain
OBJECTIVES: To develop and validate a brief questionnaire to evaluate the effects 
of gastrointestinal (GI) symptoms on HRQoL in solid-organ transplant recipients. 
METHODS: Two phases study: 1)Development of pilot version of questionnaire 
(SIGIT-QOL): bibliography review, list of areas and items included in the question-
naire, panels of 8 experts and 50 patients and questionnaire modiﬁcation to reach 
consensus and ﬁnal version, and 2)Questionnaire validation: multicenter (34 centers) 
observational 6 weeks study in solid-organ transplant recipients (kidney, liver, heart 
and lung) 3 to 12 weeks post-transplantation. Patients responded to the new question-
naire and to the GastroIntestinal Quality of Life Index-GIQLI; age, sex, transplant 
date, acute rejection and GI symptoms evaluated by physicians were registered. Psy-
chometric properties of SIGIT-QOL questionnaire (feasibility, content, construct and 
convergent validity and reliability) were evaluated. RESULTS: The ﬁrst phase gener-
ated a questionnaire of 17 items. 274 patients participated in second phase: mean age 
52.7(7.59)years, 66.3%males. Mean time from transplant 6.7(3.1) months, 44(16.4%) 
patients presented acute rejection and 44.4% GI symptoms. 95.5% patients responded 
to all items of SIGIT-QOL in 6.37(5.6) minutes vs 12.12(11.83) minutes of GIQLI. 
According to factorial analysis, all items were grouped in one dimension with a reli-
ability (Cronbach’s alpha) of 0.88. Mean score was 57.80(9.8) (theoretical range: 
0–68). A moderate, positive signiﬁcant correlation with GIQLI (r  0.67), and 
a mild negative correlation with physician’s evaluation of GI symptoms, were found. 
CONCLUSIONS: A new 17-items questionnaire SIGIT-QOL has been developed; it 
shows good feasibility, validity and reliability to evaluate the effects of gastroin- 
testinal symptoms on health related-QoL in solid-organ transplant recipients with a 
functioning graft.
PUK14
HOW DO PATIENTS DESCRIBE THEIR SYMPTOMS OF INTERSTITIAL 
CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)? QUALITATIVE 
INTERVIEWS WITH PATIENTS TO SUPPORT THE DEVELOPMENT OF  
A PATIENT-REPORTED SYMPTOM-BASED SCREENER FOR IC/PBS
Abraham L1, Arbuckle R2, Bonner N2, Crook T1, Humphrey L2, Mills IW1, Moldwin RM3, 
Nordling J4, Scholﬁeld D1, Symonds T1, van de Merwe JP5
1Pﬁzer Ltd, Sandwich, Kent, UK, 2Mapi Values Ltd, Bollington, UK, 3Long Island Jewish 
Medical Center, New York, NY, USA, 4University of Copenhagen, Herlev, Herlev, Denmark, 
5Erasmus Medical Centre, Rotterdam, CA, The Netherlands
OBJECTIVES: The National Institutes of Diabetes and Digestive and Kidney Diseases 
(NIDDK) requires cystoscopic features of interstitial cystitis (IC) as a diagnostic crite-
rion, yet this excludes signiﬁcant numbers of patients with clinical symptoms of IC/
Painful Bladder Syndrome (PBS). Patient-reported, symptom-based measures may be 
more appropriate for identifying IC/PBS patients. Existing measures have poor speci-
ﬁcity, likely due to inadequate content validity. The objective was to conduct qualita-
tive interviews with patients to identify key IC symptoms, and the language used to 
describe them, to develop a new symptom-based IC screener. METHODS: A total of 
44 IC/PBS patients with a conﬁrmed diagnosis in the US, France and Germany (aged 
22–72) were interviewed about their symptoms and subsequent impact on quality 
of life. Ten US overactive bladder (OAB) patients (aged 31–69), a condition often 
confused with IC, were also interviewed to improve speciﬁcity. Interviews included 
open-ended questions, creative tasks and focussed discussion. Thematic analysis was 
conducted utilising grounded theory methods. RESULTS: Key symptoms identiﬁed by 
IC/PBS patients were the urge to urinate, urination frequency, and pain. Urge had four 
components: 1) need to urinate driven by pain; 2) a need to urinate to avoid pain 
getting worse; 3) a constant need to urinate and; 4) a sudden need to urinate. In 
 contrast, OAB patients reported urge that did not involve pain. Both OAB and IC/PBS 
patients experienced high day and night-time urination frequency. IC pain was per-
ceived to be in the bladder, abdomen or pelvis, and was most commonly described as 
“pressure”, “burning”, “sharp” and “discomfort”. The screener items were developed 
using these data, with guidance from IC experts. CONCLUSIONS: Utilising an exten-
sive, geographically diverse interview process, we elicited key symptoms that differenti-
ate IC/PBS from OAB patients. Efforts to optimize the sensitivity and speciﬁcity of the 
new screener are critical to accurately identify patients with IC/PBS.
PUK15
STRESS URINARY INCONTINENCE: ASSESSMENT OF  
WOMEN’S PREFERENCES
Riou França L1, Zylberman M2, Launois R1
1REES France, Paris, France, 2Lilly France, SURESNES, Ile de France, France
OBJECTIVES: A French epidemiological study found that 19% of women aged 18–70           
years could be classiﬁed as having stress urinary incontinence (SUI). Our study 
explores SUI women’s willingness to seek medical treatment and their preferences 
relative to different therapeutic options. METHODS: A telephone survey was con-    
ducted among 1000 women aged 18–70 with SUI. Women willing to be treated were 
asked about their preferences between perineo-sphincter exercises, TVT surgery and 
an oral medication. A simple conjoint analysis was conducted in order to explore the 
structure of preferences between surgery and medication conditional to the probability 
of success and the out-of-the-pocket cost of therapies. Preferences about exercises were 
not assessed any further since the results of a pilot study indicated that most women 
would tend to try this therapy before any of the others. RESULTS: Fifty-ﬁve percent 
of the women are willing to try medication or surgery in the next six months. 92% 
of these women gave consistent answers in the conjoint analysis exercise. They are 
more concerned with the nature of the treatment (importance weight of 40%) than 
with having to pay a45 to try it (importance weight of 29%). According to this analy-
sis, it is predicted that 71% of these women would prefer a surgery with 95% chance 
of success and reimbursed to a medication with 60% chance of success and costing 
a45 the trial. However, when asked directly about their preferences, the estimations 
Paris Abstracts A311
are of 41% for this surgery and 30% for this medication, the remaining would choose 
neither of these treatments. CONCLUSIONS: The majority of women with SUI would       
like to be treated for their condition. If asked about their preferences for different 
treatment strategies, they tend to favour the nature of the treatment. Still, efﬁcacy and 
price issues are also taken into account.
PUK16
QUALITY OF LIFE OF ENTERIC-COATED MYCOPHENOLATE SODIUM 
(EC-MPS) IN RENAL TRANSPLANT RECIPIENTS WITH 
GASTROINTESTINAL TRACT COMPLAINTS TO MYCOPHENOLATE 
MOFETIL (MMF). MYVIDA STUDY
Andrés I1, Font B1, Mora S1, Lahoz R1, Ortega F2
1Novartis Farmaceutica SA, Barcelona, Spain, 2Hospital Universitario Central de Asturias, 
Oviedo, Spain
OBJECTIVES: To assess the effect of conversion from MMF to EC-MPS on QoL in 
renal transplantation (RTx) recipients who need dose reduction due to GI symptoms. 
METHODS: Multicenter, open-label, MMF-controlled, 12-weeks trial. RTx patients 
taking MMF who had previously reported GI adverse events were randomized to 
EC-MPS (n  70, equimolar dose for 0–2 wk, dose optimization until maximum toler-
ated dose or 720 mg bid for 2–6 wk and maintenance dose for 6–12 wk); or continue 
MMF (n  64, same dose adjustment). Primary endpoint was Gastrointestinal Quality 
of Life Index (GIQLI); secondary endpoints were Gastrointestinal Symptom Rating 
Scale (GSRS), Psychological General Well-Being Index (PGWBI), Overall Treatment 
Effect (OTE) and optimization of doses of MPA. RESULTS: GIQLI scores were sig-
niﬁcantly better in EC-MPS groups at 12 wk (110.1 vs 97.2 points, p  0.0136). Mean 
adjusted scores were also signiﬁcantly in this group for all secondary scales used 
(GSRS: 36.3 vs 29.2 points, p  0.0017; PGWBI: 78.1 vs 72.4 points, p  0.0343). 
OTE evaluation of GI symptoms was signiﬁcantly better for the EC-MPS group 
(p  0.0145-patients and p  0.0006-physicians). The number of patients receiving 
intermediate doses of MPA (EC-MPS/720 mg–MMF/1000 mg) at 12 weeks was sig-
niﬁcantly higher in EC-MPS group (55.4% vs 27.4%, p  0.003). More patients with 
MMF were receiving low doses than with EC-MPS (35.6% vs 10.3%, p  0.0004). 
In MMF group a higher percentage of patients did not raise the dosage from baseline 
(23.5% for MMF and 8.9% for EC-MPS group, p  0.004). CONCLUSIONS: EC-
MPS improves gastrointestinal quality of life in renal transplant patients with GI 
complaints to MMF, as it allows an optimization of MPA dose without increasing 
GI-related symptom burden.
URINARY/KIDNEY DISORDERS – Health Care Use & Policy Studies
PUK17
CHRONIC OPIOID THERAPY IN ELDERLY PATIENTS WITH IMPAIRED 
RENAL FUNCTION OR WITH A HIGH RISK OF KIDNEY FAILURE  
IN GERMANY
Biteeva I1, Kruse S2
1Janssen-Cilag, Neuss, NRW, Germany, 2Janssen-Cilag GmbH, Neuss, NRW, Germany
OBJECTIVES: Elderly patients with impaired renal function or with a risk of kidney 
failure due to diabetes mellitus (DM) or with hypertension are at risk for accumulation 
of metabolites from certain opioids as well as for drug-drug interactions (DDI) because 
of their multimorbidity. The purpose of this analysis is to analyze the share of patients 
treated with opioids prone to accumulation of metabolites (e.g. morphine) or DDI via 
CYP450 (e.g. oxycodone, tramadole) in Germany. METHODS: This study was per-
formed using retrospective longitudinal aggregated patient data from the IMS Disease 
Analyzer. All patients 65 years or older with at least one diagnosis of DM (ICD10 
E10-E14), hypertension (I10-I15), renal failure (N17-N19), glomerular disease (N00-
N08) or renal tubulo-interstitial disease (N10-N16) with at least two prescriptions of 
extended-release (ER) morphine, hydromorphone, oxycodone or tramadole in 2008 
were included. The “P450 Drug Interaction Table” of the Indiana University was used 
as the source for substances with potential DDI. RESULTS: A total of 6565 patients 
aged 65 years or more with at least two ER opioids prescriptions in 2008 met the 
criteria of the high risk group for DDI and metabolite accumulation because of 
impaired renal function/ risk of kidney failure. A total of 702 (10.7%) patients from 
this group were treated with morphine, 528 (8.0)% with hydromorphone, 1.603 
(24.4%) with oxycodone, 3.732 (56.8%) with tramadole. Fifty-two percent of patients 
treated with oxycodone and 44% of those treated with tramadole concomitantly 
received a systemic therapy with a potential risk of DDI. CONCLUSIONS: The major-
ity of patients were treated with an opioid prone to accumulation of metabolites or 
DDI that can cause additional costs. For this group of patients the choice of hydro-
morphone can possibly avoid these potential complications.
POSTER SESSION II
CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT—
ACE INHIBITOR INDUCED COUGH
Vegter S, Boersma C, De Jong-van den Berg LTW
University of Groningen, Groningen, The Netherlands
OBJECTIVES: Angiotensin converting enzyme inhibitors (ACEi) are frequently pres-       
cribed for various cardiac and renal diseases. A common side-effect of these drugs is 
a persistent dry cough. Physicians who fail to recognise a dry cough to be ACEi related 
may attemp to treat it with antitussive agents, in stead of recommended ACEi substi-
tution. Prescription behaviour in the general population considering treatment of the 
side-effect with antitussive agents has not been studied before. METHODS: Drug 
dispensing data between 2000 and 2007 were retrieved from the IADB.nl database.  
A prescription sequence symmetry analysis was used to determine whether antitussive           
agents were prescibed more often following ACEi initiation than the other way 
around. A logistic regression model was ﬁtted to determine predictors.        RESULTS: A 
total of 1054 patients were incident users of both ACEi and antitussives within a            
half-year time span. There was an excess of patients being prescibed antitussive agents 
after ACEi initiation, adjusted Sequence Ratio 2.2 (CI: 1.9–2.4). Females were more 
likely to be prescribed antitussive agents following ACEi therapy initiation, Odds 
Ratio 1.4 (CI: 1.1–1.9), age and comedications were no signiﬁcant predictors. CON-
CLUSIONS: There was a signiﬁcant and clinically relevant excess of patients receiving           
antitussives after ACEi initiation. The results suggest that cough as a side-effect of 
ACEi is not recognized as being ACEi related or is symptomatically treated with 
antitussive agents in stead of ACEi substitution. The estimated frequency of antitussive 
treatment of ACEi induced dry cough is 15%. Further results will be presented on 
cost implications of unnecassary drug use and decreased ACEi therapy compliance.
PCV2
INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS 
WITH UNTREATED PRIMARY HYPERPARATHYROIDISM
Yu N, Leese GP, Donnan PT
University of Dundee, Dundee, UK
OBJECTIVES: Primary hyperparathyroidism (PHPT) is the third most common endo-
crine disorder, with the majority changed being asymptomatic. Parathyroidectomy 
(PTX), as the only deﬁnite treatment, is available to severe PHPT (~20%). We evalu-
ated the mortality and co-morbidities in patients with PHPT with aim to estimate 
long-term impact of those untreated patients on the health care system. METHODS: 
This is a retrospective population-based cohort study. Using a unique patient identiﬁer 
in Tayside, Scotland, electronic record-linkage enabled a dataset of PHPT patients to 
be created from an algorithm of biochemistry and nuclear scan records, hospital 
admission data and community based prescriptions. Three additional datasets were 
added in order to measure the mortality and co-morbidities in comparison with the 
general population using standardised mortality/morbidity ratios (SMRs) and stan-
dardised incidence ratios (SIRs). Patients were split into ‘mild’ and ‘aggressive’ groups 
broadly following the NIH criteria for PTX. RESULTS: During the decade of 1997 
to 2006, we identiﬁed 2299 patients (70.4% female), 1683 (73.2%) as having mild 
PHPT. A third of the aggressive PHPT patients (32.8%) had undergone PTX. We 
found an increased risk of all-cause mortality (SMR: 2.58, 95% CI (2.39–2.79)) 
as well as cardiovascular and cancer related deaths (SMR: 2.49 (2.21–2.80); 3.02 
(2.60–3.48) respectively) in all patients. The risk is similar between the mild and 
the unoperated aggressive groups, but slightly reduced in the operated group. Unoper-
ated patients (both mild and aggressive) were also associated with high risk of co-
morbidities, with renal disease being the highest. Surgery signiﬁcantly improved 
patients’ health outcomes. CONCLUSIONS: The population prevalence of PHPT 
has generally increased; incidence is greater in females and increases with age. 
Mortality and morbidity are similarly higher for patients with mild and unoperated 
aggressive PHPT. Surgery may be worth recommending to all patients, and further 
study of the cost-effectiveness of surgery and chemotherapy is planned.
PCV3
USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE 
HEARTH FAILURE
Lachaine J1, Beauchemin C2, Ramos É3
1University of Montreal, Montréal, QC, Canada, 2University of Montreal, Montreal, QC, 
Canada, 3Pﬁzer Canada Inc, Kirkland, QC, Canada
OBJECTIVES: Aldosterone plays an important role in the pathophysiology of conges-
tive heart failure (CHF). Blockade of aldosterone receptors by spironolactone substan-
tially reduces risk of morbidity and mortality among patients with CHF. However, 
beneﬁts of spironolactone are potentially limited by its treatment compliance and 
adverse events proﬁle, particularly hyperkalemia and gynecomastia. The purpose of 
this study was to estimate the use of spironolactone in patients with CHF, the inci-
dence of key adverse events and patients compliance to spironolactone. METHODS: 
This study was performed using data from the Quebec provincial medical and drug 
plans (RAMQ). Data on medical and pharmaceutical services from January 2000 to 
September 2008 were obtained from the RAMQ for patients who had a diagnosis of 
CHF (ICD-9 codes  4280–4289) during that period. Relative incidence of gyneco-
mastia and hyperkalemia was estimated for users and non users of spironolactone. 
Treatment adherence was estimated for initial users of spironolactone and compared 
